Strides Pharma Science liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

3.17×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.25×	1.25×	1.20×	1.03×	1.05×
0.68×	0.68×	0.70×	0.64×	0.67×
137	189	182	267	354
902	717	507	89.7	145

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

STAR₹1,001.10

Strides Pharma Science Ltd.

· Pharma & Health

₹ CrorePeersSPARC SUPRIYA SHILPAMED THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹9,227 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	3.17
Current Ratio	1.05	1.03	1.20	1.25	1.25
Quick Ratio	0.67	0.64	0.70	0.68	0.68
Cash, Equiv & ST Investments	354.3	266.8	182.1	188.7	137.3
Working Capital	145.0	89.7	507.4	717.3	902.2

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.